Skip to content
logo
  • Home
  • About
    • About TnSam
    • Our Team
    • PEACE
  • Resources
    • About Addiction
    • TnSAM NEWS
    • Links
  • TnSAM NEWS
  • Contacts
  • Members
    • Login
    • My TNSAM Account
    • Members Roster
    • Chapter Announcements
    • Chapter Meetings Minutes & Agendas
    • Member’s Only Discussions
    • Chapter Documents & Presentations
      • Officer Roles
      • Chapter Charter
      • Chapter Agreement
      • Chapter Constitution
      • Presentations
  • Public Resources
logo
  • Home
  • About
    • About TnSam
    • Our Team
    • PEACE
  • Resources
    • About Addiction
    • TnSAM NEWS
    • Links
  • TnSAM NEWS
  • Contacts
  • Members
    • Login
    • My TNSAM Account
    • Members Roster
    • Chapter Announcements
    • Chapter Meetings Minutes & Agendas
    • Member’s Only Discussions
    • Chapter Documents & Presentations
      • Officer Roles
      • Chapter Charter
      • Chapter Agreement
      • Chapter Constitution
      • Presentations
  • Public Resources
  • Home
  • About
    • About TnSam
    • Our Team
    • PEACE
  • Resources
    • About Addiction
    • TnSAM NEWS
    • Links
  • TnSAM NEWS
  • Contacts
  • Members
    • Login
    • My TNSAM Account
    • Members Roster
    • Chapter Announcements
    • Chapter Meetings Minutes & Agendas
    • Member’s Only Discussions
    • Chapter Documents & Presentations
      • Officer Roles
      • Chapter Charter
      • Chapter Agreement
      • Chapter Constitution
      • Presentations
  • Public Resources
Articles of Interest Legislative/Regulatory
0
0
February 1, 2023

DEA Announces Important Change to Registration Requirement

Dear DEA Registrant:

On December 29, 2022, with the signing of the Consolidated Appropriations Act of 2023 (the Act), Congress eliminated the “DATA-Waiver Program.”
DEA fully supports this significant policy reform. At this moment, when the United States is suffering tens of thousands of opioid-related drug poisoning deaths every year, the DEA’s top priority is doing everything in its power to save lives. Medication for opioid use disorder helps those who are fighting to overcome opioid use disorder by sustaining recovery and preventing overdoses. At DEA, our goal is simple: we want medication for opioid use disorder to be readily and safely available to anyone in the country who needs it. The elimination of the X-Waiver will increase access to buprenorphine for those in need.
All DEA registrants should be aware of the following:
  • A DATA-Waiver registration is no longer required to treat patients with buprenorphine for opioid use disorder.
  • Going forward, all prescriptions for buprenorphine only require a standard DEA registration number. The previously used DATA-Waiver registration numbers are no longer needed for any prescription.
  • There are no longer any limits or patient caps on the number of patients a prescriber may treat for opioid use disorder with buprenorphine.
  • The Act does not impact existing state laws or regulations that may be applicable.
Separately, the Act also introduced new training requirements for all prescribers. These requirements will not go into effect until June 21, 2023. The DEA and SAMHSA are actively working to provide further guidance and DEA will follow up with additional information on these requirements shortly. Importantly, these new requirements do not impact the changes related to the elimination of the DATA-Waiver Program described above.
Sincerely,
Anne Milgram
Administrator
For information regarding DEA’s Diversion Control Division, please visit https://www.DEAdiversion.usdoj.gov.  Please contact the Diversion Control Division Policy Section at ODLP@dea.gov if you seek additional assistance regarding this or any other matter.
See original signed document.
Tennessee Society of Addiction Medicine
Author: Tennessee Society of Addiction Medicine

Share

Post navigation

Prev
Next

Leave a Comment Cancel reply

Your email address will not be published. Required fields are marked *

The Tennessee Society of Addiction Medicine 

TNSAM LOGO

head office

207 Spears Avenue, Chattanooga, TN 37405

apzotos@gmail.com

tel: (423) 316-8147

Recent Posts

  • HB309/SB1072 Decriminalization of Marijuana March 8, 2023
  • DEA Announces Proposed Rules for Permanent Telemedicine Flexibilities March 7, 2023

Quick News

Another Brilliant Design by: Adwebvertising…It’s Like Advertising…Only Better!

Copyright © 2021, Tennessee Society of Addiction Medicine. All Rights Reserved